U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06810791) titled 'HVA vs IA/DA or VA in the Treatment of ND HR-AML' on Jan. 16.
Brief Summary: The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed high-risk AML patients.
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
Newly Diagnosed Acute Myeloid Leukemia With High Risk
Intervention:
DRUG: HVA
Homoharringtonine (HHT) is given by venous drip daily at 1 mg/m2 from day 1 to 7. Venetoclax (VEN) is given 100 mg on day 1, 200 mg on day 2, and 400 mg orally from...